News & Updates
Filter by Specialty:
177Lu-PSMA-617 improves rPFS vs ARPI switch in taxane-naïve mCRPC patients
The prostate-specific membrane antigen (PSMA)–targeted radioligand, lutetium-177 (177Lu)–PSMA-617, improves radiographic progression-free survival (rPFS) vs androgen receptor pathway inhibitor (ARPI) switch and has a favourable safety profile in taxane-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on one prior second-generation ARPI, results of the phase III PSMAfore trial have shown.
177Lu-PSMA-617 improves rPFS vs ARPI switch in taxane-naïve mCRPC patients
14 Nov 2023
Pyrotinib plus trastuzumab-docetaxel prolongs PFS in breast cancer
Treatment with pyrotinib in combination with trastuzumab and docetaxel (tras/doc) results in longer progression-free survival (PFS) than placebo combined with tras/doc in patients with untreated HER2-positive metastatic breast cancer, a study has shown. In addition, the safely profile of tras/doc plus pyrotinib is manageable.
Pyrotinib plus trastuzumab-docetaxel prolongs PFS in breast cancer
10 Nov 2023
Nodal staging before SBRT does not affect survival in early-stage NSCLC
Patients with early-stage nonsmall cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) have similar overall survival (OS) regardless of nodal staging, reports a study. In addition, use of SBRT has shown a steady increase over the study period.
Nodal staging before SBRT does not affect survival in early-stage NSCLC
09 Nov 2023
LIPI score predicts survival in NSCLC patients treated with PD-1/PD-L1 inhibitor plus chemo
Use of the lung immune prognostic index (LIPI) score can help predict the efficacy of combination therapy of programmed cell death (PD)-1/PD-ligand 1 (PD-L1) blockade and chemotherapy (CT) in patients with advanced nonsmall cell lung cancer (NSCLC), suggests a study.
LIPI score predicts survival in NSCLC patients treated with PD-1/PD-L1 inhibitor plus chemo
08 Nov 2023
Neoadjuvant immunotherapy delivers better response in NSCLC
Patients with nonsmall cell lung cancer (NSCLC) who have been treated with neoadjuvant immunotherapy show greater response than those treated with neoadjuvant chemotherapy (CT), as shown in a study. Treatment-related adverse events (TRAEs) are similar between the two groups.
Neoadjuvant immunotherapy delivers better response in NSCLC
08 Nov 2023
Serum vitamin A, E forms tied to prostate cancer risk
Several forms of serum vitamin A and E were associated with prostate cancer risk, with significant effect modification by smoking and alcohol consumption status, according to an analysis that used data from the Singapore Prostate Cancer Study.